In this issue:
Changes in treatment selections for advanced urothelial cancer following FDA approval for avelumab
Durvalumab & radiation therapy for localised bladder cancer
Neoadjuvant chemotherapy with gemcitabine & split-dose cisplatin in high-risk UTUC
Prognosis of Ta G3 NMIBC vs. Ta G2 & T1 G3 tumours
No significant difference in RFS for hyperthermic vs. normothermic MMC in intermediate-risk NMIBC
Diagnostic efficacy of urinary DNA in detecting bladder cancer
Long-term outcomes of intravesical gemcitabine + docetaxel for high-risk NMIBC after BCG failure
1-year study of all BCG therapy dispensations for NMIBC in France
Disease-free survival in high-risk muscle-invasive urothelial cancer by CPS & tumour cell score
TAR-200: a novel, intravesical drug delivery system for MIBC
Please login below to download this issue (PDF)